Gary Hattersley - 20 Nov 2025 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Nov 2025, 16:09:42 UTC
Prior SEC filing
29 Oct 2025
Next SEC filing
03 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stephen Dang, Attorney-in-Fact

Key filing fact

Gary Hattersley filed Form 4 for Nuvation Bio Inc. (NUVB) on 24 Nov 2025.

Key facts

  • This page summarizes Gary Hattersley's Form 4 filing for Nuvation Bio Inc. (NUVB).
  • 6 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 24 Nov 2025, 16:09.

Change

  • Previous filing in this sequence was filed on 29 Oct 2025.
  • Current net transaction value: -$1,964,983.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001521111 Primary reporting owner

Hattersley Gary

Relationship
CHIEF SCIENTIFIC OFFICER
Address
C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK
Signature
/s/ Stephen Dang, Attorney-in-Fact
Signature date
24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVB transaction

Class A Common Stock

Options Exercise

Transaction value
$120,149
Shares
+69,051
Change %
Price
$1.74
Shares after
69,051
Date
20 Nov 2025
Ownership
Direct
NUVB transaction

Class A Common Stock

Sale

Transaction value
$499,032
Shares
-69,051
Change %
-100%
Price
$7.23
Shares after
0
Date
20 Nov 2025
Ownership
Direct
Footnotes
F1
NUVB transaction

Class A Common Stock

Options Exercise

Transaction value
$582,000
Shares
+300,000
Change %
Price
$1.94
Shares after
300,000
Date
20 Nov 2025
Ownership
Direct
NUVB transaction

Class A Common Stock

Sale

Transaction value
$2,168,100
Shares
-300,000
Change %
-100%
Price
$7.23
Shares after
0
Date
20 Nov 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-69,051
Change %
-23%
Price
$0.000000
Shares after
229,884
Date
20 Nov 2025
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
69,051
Exercise price
$1.74
Footnotes
F2
NUVB transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-300,000
Change %
-60%
Price
$0.000000
Shares after
200,000
Date
20 Nov 2025
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
300,000
Exercise price
$1.94
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F2

Options vested as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.

Footnote F3

Options vested as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .